ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1628

A Novel Histone Deacetylase 6 Inhibitor, CKD-H059 Inhibits the Inflammatory Response in Rheumatoid Arthritis

Yu Jin Jang1, Bo Ram Oh2, Hyojin Lim3, Daekwon Bae3, Nina Ha3, Young il Choi4, Jin Kyun Park5, Eun Young Lee5, Eun Bong Lee5 and Yeong Wook Song5,6, 1Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Parmarcy, Seoul National University, Seoul, South Korea, 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, South Korea, 3Department of Pharmacology and Toxicology, CKD Research Institute, CKD Pharmaceutical Company, Seoul, South Korea, 4315-20 dongbaekjukjeon-daero, giheung-gu, Pharmacology lab, Hyo-Jong Research Laboratories, CKD Pharmaceutical Company, Yongin-si, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 6Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: histone acetylation, regulatory cells and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Epigenetic changes including histone modification play an important role in development of rheumatoid arthritis (RA). Histone deacetylase inhibitor (HDACi) increases transcription of numerous genes by rendering chromatin state more accessible for transcription factor and RNA-polymerase, leading to anti-proliferative and anti-inflammatory effects. In addition, direct change in acetylation state of cellular proteins may alter cellular function. 

This study was aimed to investigate the effects of CKD-H059, a novel HDAC-6 inhibitor, on regulatory T (Treg) cells and fibroblast-like-synoviocytes (FLS) of RA patients in vitro and on development of arthritis in vivo.

Methods: Regulatory T cells (iTreg) were induced from naïve CD4+ T cells of RA patients. CSFE labeled effector T cells (Teff) from healthy subjects were co-cultured with iTreg in the increasing concentrations of CKD-H059 and Teff proliferation was analyzed by flow cytometry. After 24 hour activation with IL-1β in the increasing concentrations of CKD-H059, proliferation and IL-6 production of RA-FLS were assessed. Cytoplasmic acetylation of α-tubulin in the activated RA-FLS was visualized by confocal microscopy. Adjuvant-induced arthritis (AIA) was induced in mice that were treated with oral CKD-H059 (3, 10, 30, 50, 100 mg/kg) and the severity of arthritis was assessed on 9, 13, and 16 days.

Results: In the presence of CKD-H059, iTreg efficiently inhibited the proliferation of Teff in a dose dependent manner. CKD-H059 induced acetylation of α-tubulin in cytoskeleton with subsequent cell morphology change (i.e. from long spindle form into round flat cells) and inhibited cell proliferation and production of pro-inflammatory cytokine IL-6. In AIA mice, oral CKD-H059 was able to prevent the development of clinical arthritis in a dose-dependent manner.

Conclusion: The novel HDAC6 inhibitor CKD-H059 inhibits the inflammatory response in T cells and FLS of RA in vitro and ameliorates arthritis severity in vivo. Therefore, CKD-H059 might offer a novel treatment option for RA.


Disclosure: Y. J. Jang, None; B. R. Oh, None; H. Lim, None; D. Bae, None; N. Ha, None; Y. I. Choi, None; J. K. Park, None; E. Y. Lee, None; E. B. Lee, None; Y. W. Song, None.

To cite this abstract in AMA style:

Jang YJ, Oh BR, Lim H, Bae D, Ha N, Choi YI, Park JK, Lee EY, Lee EB, Song YW. A Novel Histone Deacetylase 6 Inhibitor, CKD-H059 Inhibits the Inflammatory Response in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/a-novel-histone-deacetylase-6-inhibitor-ckd-h059-inhibits-the-inflammatory-response-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-histone-deacetylase-6-inhibitor-ckd-h059-inhibits-the-inflammatory-response-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology